52 results
10-K
2023 FY
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
-kickback, fraud and abuse, false claims, and transparency laws and regulations related to drug pricing and payments and other transfers of value made … reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.
Our research and development activities could be affected
10-K
2023 FY
EX-10.22
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
act of dishonesty, fraud, or misrepresentation in relation to Executive’s duties to the Company which act is materially and demonstrably injurious
10-K
EX-31.1
ha0gav94nsfdzeabi2qr
7 Mar 24
Annual report
4:05pm
10-K
EX-10.23
jmsjrfwbsp32787c pmn
7 Mar 24
Annual report
4:05pm
10-K
EX-31.2
lq6i77
7 Mar 24
Annual report
4:05pm
10-Q
EX-31.1
ka6x7j7 t0yvkg0a
1 Nov 23
Quarterly report
4:05pm
10-Q
EX-31.2
d9j5o0
1 Nov 23
Quarterly report
4:05pm
S-8
EX-99.1
ed3960f
19 Sep 23
Registration of securities for employees
9:57pm
S-8
EX-99.3
h22u9
19 Sep 23
Registration of securities for employees
9:57pm
8-K
EX-3.2
gy75i6yuk5h
19 Sep 23
Amendments to Articles of Incorporation or Bylaws
4:16pm
424B4
3citv7 edtqd9d
18 Sep 23
Prospectus supplement with pricing info
4:12pm
S-1/A
bkdxf 967u1nj
11 Sep 23
IPO registration (amended)
6:07am
S-1/A
EX-1.1
aezcqcjb0lukiu
11 Sep 23
IPO registration (amended)
6:07am
S-1
EX-3.3
intu6 9ot6a7
25 Aug 23
IPO registration
5:03pm
S-1
EX-2.1
qvcqbtcfkhu54
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.6
zia 7cxvlf9nf
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.7
jx6w8r03r
25 Aug 23
IPO registration
5:03pm